Literature DB >> 24732809

The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism.

Jianrong Lu1, Ming Tan2, Qingsong Cai3.   

Abstract

Compared to normal cells, cancer cells strongly upregulate glucose uptake and glycolysis to give rise to increased yield of intermediate glycolytic metabolites and the end product pyruvate. Moreover, glycolysis is uncoupled from the mitochondrial tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) in cancer cells. Consequently, the majority of glycolysis-derived pyruvate is diverted to lactate fermentation and kept away from mitochondrial oxidative metabolism. This metabolic phenotype is known as the Warburg effect. While it has become widely accepted that the glycolytic intermediates provide essential anabolic support for cell proliferation and tumor growth, it remains largely elusive whether and how the Warburg metabolic phenotype may play a role in tumor progression. We hereby review the cause and consequence of the restrained oxidative metabolism, in particular in the context of tumor metastasis. Cells change or lose their extracellular matrix during the metastatic process. Inadequate/inappropriate matrix attachment generates reactive oxygen species (ROS) and causes a specific type of cell death, termed anoikis, in normal cells. Although anoikis is a barrier to metastasis, cancer cells have often acquired elevated threshold for anoikis and hence heightened metastatic potential. As ROS are inherent byproducts of oxidative metabolism, forced stimulation of glucose oxidation in cancer cells raises oxidative stress and restores cells' sensitivity to anoikis. Therefore, by limiting the pyruvate flux into mitochondrial oxidative metabolism, the Warburg effect enables cancer cells to avoid excess ROS generation from mitochondrial respiration and thus gain increased anoikis resistance and survival advantage for metastasis. Consistent with this notion, pro-metastatic transcription factors HIF and Snail attenuate oxidative metabolism, whereas tumor suppressor p53 and metastasis suppressor KISS1 promote mitochondrial oxidation. Collectively, these findings reveal mitochondrial oxidative metabolism as a critical suppressor of metastasis and justify metabolic therapies for potential prevention/intervention of tumor metastasis.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anoikis; Glycolysis; Metastasis; OXPHOS; ROS; Warburg effect

Mesh:

Substances:

Year:  2014        PMID: 24732809      PMCID: PMC4195816          DOI: 10.1016/j.canlet.2014.04.001

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  95 in total

1.  Different kinds of reactive oxygen and nitrogen species were detected in colon and breast tumors.

Authors:  G Haklar; E Sayin-Ozveri; M Yüksel; A O Aktan; A S Yalçin
Journal:  Cancer Lett       Date:  2001-04-26       Impact factor: 8.679

2.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

Review 3.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

Review 4.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

5.  Dichloroacetate in the treatment of lactic acidosis.

Authors:  P W Stacpoole; A C Lorenz; R G Thomas; E M Harman
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

6.  Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer.

Authors:  Chun-Wun Lu; Shau-Chieh Lin; Chun-Wei Chien; Shih-Chieh Lin; Chung-Ta Lee; Bo-Wen Lin; Jenq-Chang Lee; Shaw-Jenq Tsai
Journal:  Am J Pathol       Date:  2011-07-18       Impact factor: 4.307

7.  Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species.

Authors:  K A Brand; U Hermfisse
Journal:  FASEB J       Date:  1997-04       Impact factor: 5.191

8.  p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2.

Authors:  Tanupriya Contractor; Chris R Harris
Journal:  Cancer Res       Date:  2011-11-28       Impact factor: 12.701

9.  Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm?

Authors:  Ioanna Papandreou; Tereza Goliasova; Nicholas C Denko
Journal:  Int J Cancer       Date:  2010-12-07       Impact factor: 7.396

10.  Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis.

Authors:  X Liu; X Wang; J Zhang; E K Y Lam; V Y Shin; A S L Cheng; J Yu; F K L Chan; J J Y Sung; H C Jin
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

View more
  199 in total

1.  A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.

Authors:  Bronwyn Scott; Jianliang Shen; Sara Nizzero; Kathryn Boom; Stefano Persano; Yu Mi; Xuewu Liu; Yuliang Zhao; Elvin Blanco; Haifa Shen; Mauro Ferrari; Joy Wolfram
Journal:  Pharmacol Res       Date:  2016-07-06       Impact factor: 7.658

2.  Two dichloric compounds inhibit in vivo U87 xenograft tumor growth.

Authors:  Dmitriy Ovcharenko; Catrina Chitjian; Alex Kashkin; Alex Fanelli; Victor Ovcharenko
Journal:  Cancer Biol Ther       Date:  2019-06-24       Impact factor: 4.742

3.  Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin.

Authors:  N V Rajeshkumar; Shinichi Yabuuchi; Shweta G Pai; Elizabeth De Oliveira; Jurre J Kamphorst; Joshua D Rabinowitz; Héctor Tejero; Fátima Al-Shahrour; Manuel Hidalgo; Anirban Maitra; Chi V Dang
Journal:  Clin Cancer Res       Date:  2017-06-13       Impact factor: 12.531

Review 4.  Pheochromocytoma: The First Metabolic Endocrine Cancer.

Authors:  Ivana Jochmanova; Karel Pacak
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

5.  BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose.

Authors:  Federico Lucantoni; Heiko Düssmann; Irene Llorente-Folch; Jochen H M Prehn
Journal:  Oncotarget       Date:  2018-05-25

6.  Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma.

Authors:  Juliana Guimarães Santos; Wanise Maria Souza Da Cruz; Axel H Schönthal; Marcela D'alincourt Salazar; Cristina Asvolinsque Pantaleão Fontes; Thereza Quirico-Santos; Clovis Orlando Da Fonseca
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

7.  Metabolic Reprogramming Promotes Neural Crest Migration via Yap/Tead Signaling.

Authors:  Debadrita Bhattacharya; Ana Paula Azambuja; Marcos Simoes-Costa
Journal:  Dev Cell       Date:  2020-04-02       Impact factor: 12.270

8.  Gram-negative bacteria facilitate tumor outgrowth and metastasis by promoting lipid synthesis in lung cancer patients.

Authors:  Maosong Ye; Xia Gu; Yang Han; Meiling Jin; Tao Ren
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

Review 9.  The sesquiterpene α-bisabolol in the adipocyte-cancer desmoplastic crosstalk: does it have an action on epithelial-mesenchymal transition mechanisms?

Authors:  Salvatore Chirumbolo; Geir Bjørklund
Journal:  Int J Clin Oncol       Date:  2016-12-09       Impact factor: 3.402

10.  Equating salivary lactate dehydrogenase (LDH) with LDH-5 expression in patients with oral squamous cell carcinoma: An insight into metabolic reprogramming of cancer cell as a predictor of aggressive phenotype.

Authors:  Tajindra Singh Saluja; Anita Spadigam; Anita Dhupar; Shaheen Syed
Journal:  Tumour Biol       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.